Innate Pharma SA

Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Its product pipeline include Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that lacutamab, an anti-KIR3DL2 antibody, demonstrated clinical responses in patients with mycosis fungoides (MF), in the ongoing Phase 2 TELLOMAK clinical trial. The results will be shared in an oral presentation at the EORTC CLTG1 Annual Meeting, taking place from 22-24 September 2022 in Madrid, Spain, presented by Pr. Martine Bagot, Head of the

Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides

Innate Pharma S.A. (NASDAQ:IPHA ) First Half 2022 Financial Results and Business Update September 15, 2022 8:00 AM ET Company Participants Henry Wheeler – Investor Relations Mondher Mahjoubi – Chief Executive Officer Joyson Karakunnel – Executive Vice President and Chief Medical Officer Yannis Morel – Executive Vice President-Business Development and Product Portfolio Strategy Frédéric Lombard – Chief Financial Officer Conference Call Participants Carly Kenselaar – Citi Daina Graybosch – SVB Securities Nick Hallatt – Goldman Sachs Olga Smolentseva – Bryan Garnier Henry Wheeler Good morning and good afternoon and welcome everybody.

Innate Pharma S.A. (IPHA) First Half 2022 Financial Results and Business Update Transcript

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma reports first half 2022 financial results and business update

Innate Pharma Reports First Half 2022 Financial Results and Business Update

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast for first half 2022 business update

Innate Pharma Announces Conference Call and Webcast for First Half 2022 Business Update

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the following presentations will be presented at the ESMO (European Society for Medical Oncology) Annual Meeting 2022 taking place from 9 to 13 September 2022, in Paris, France. A multi-center Phase Ib trial evaluating the safety and efficacy of lacutamab in patients with relapsed/refractory peripheral T-cell lymphoma that express KIR3DL2 - A

Innate Pharma to Present Lacutamab PTCL Phase 1b Design and ANKET™ Platform at ESMO 2022

The stock price of Innate Pharma (IPHA) fell by over 7% during intraday trading today. This is why.

Innate Pharma (IPHA) Stock: Why It Fell Over 7% Today

AstraZeneca

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that a planned futility interim analysis of the INTERLINK-1 Phase 3 study sponsored by AstraZeneca (LSE/STO/Nasdaq: AZN) did not meet a pre-defined threshold for efficacy. Based on this result and the recommendation of an Independent Data Monitoring Committee, AstraZeneca has informed Innate that the study will be discontinued. There were no new

Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that Sanofi has made the decision to progress IPH6401/SAR'514 into investigational new drug (IND)-enabling studies, triggering a €3 million milestone payment. IPH6401/SAR'514 is a BCMA-targeting NK cell engager using Sanofi's proprietary CROSSODILE® multi-functional platform, which comprises the Cross-Over-Dual-Variable-Domain (CODV) format. It in

Second Innate Pharma NK Cell Engager Selected by Sanofi as Drug Candidate for Development

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces IPH5201 Phase 2 study in lung cancer

Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced the voting results of its shareholders at the Annual General Meeting (“AGM”), which took place on May 20, 2022, in Marseille. All resolutions were voted on in accordance with the Executive Board's recommendations. A total of 134 votes were cast out of a total of 32,598,725 shares giving right to 33,088,040 voting rights, representing a quorum of 40.88%.

Outcome of Innate Pharma's 2022 Annual General Meeting

Innate Pharma SA (NASDAQ:IPHA ) Q1 2022 Earnings Conference Call May 10, 2022 8:00 AM ET Company Participants Henry Wheeler - VP and Head of IR Mondher Mahjoubi - Chairman of Executive Board and CEO Joyson Karakunnel - Executive VP and Chief Medical Officer Yannis Morel - Executive VP of Product Portfolio Strategy and Business Development and Member of Executive Board Conference Call Participants Daina Graybosch - SVB Leerink Olga Smolentseva - Bryan Garnier Jingming Chen - Evercore Arthur He - H.C. Wainwright Operator Good morning, everyone.

Innate Pharma SA (IPHA) CEO Mondher Mahjoubi on Q1 2022 Results - Earnings Call Transcript

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma reports first quarter 2022 financial results and business update

Innate Pharma Reports First Quarter 2022 Financial Results and Business Update

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it has filed a prospectus supplement with the Securities and Exchange Commission (“SEC”) relating to an At-The-Market (“ATM”) program. Pursuant to this program, the Company may offer and sell to eligible investors (as described below) a total gross amount of up to $75 million of American Depositary Shares (“ADS”), each ADS representing one or

Innate Pharma Establishes an At-The-Market (“ATM”) Program on Nasdaq

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Tuesday, May 10, 2022 at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first quarter of 2022. Speakers during the call will be: Mondher Mahjoubi, Chief Executive Officer Joyson Karakunnel, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice Pres

Innate Pharma Announces Conference Call and Webcast for Q1 2022 Business Update

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) has now dosed the first patient in its Phase 3 clinical trial, PACIFIC-9, evaluating durvalumab (PD-L1) in combination with monalizumab (NKG2A) or AstraZeneca's oleclumab (anti-CD73) in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) who have not progressed following definitive platin

Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to hold its Annual General Meeting of shareholders on May 20, 2022

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 20, 2022

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma files its 2021 universal registration document and 2021 annual report on Form 20-F

Innate Pharma Files Its 2021 Universal Registration Document (Document d'enregistrement universel) and 2021 Annual Report on Form 20-F

Innate Pharma S.A. (IPHA) CEO Mondher Mahjoubi on Q4 2021 Results - Earnings Call Transcript

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma reports Full Year 2021 financial results and business update

Innate Pharma Reports Full Year 2021 Financial Results and Business Update

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast for full year 2021 financial results

Innate Pharma Announces Conference Call and Webcast for Full Year 2021 Financial Results

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma obtains €28.7M in non-dilutive financing in the form of State Guaranteed Loans

Innate Pharma Obtains €28.7m in Non-Dilutive Financing in the Form of State Guaranteed Loans

MARSEILLE, France--(BUSINESS WIRE)--First patient dosed in IPH6101/SAR443579 Phase 1/2 clinical trial in various blood cancers

Innate Pharma: First Patient Dosed in IPH6101/SAR443579 Phase 1/2 Clinical Trial in Various Blood Cancers

Innate Pharma SA's (NASDAQ: IPHA) data from the Phase 2 expansion cohort (cohort 3) evaluating the monalizumab triplet combination shows preliminary activity and an acceptable safety profile with a low discontinuation rate. Cohort 3 is exploring the triplet combination of monalizumab, cetuximab, and durvalumab in the first-line treatment of patients with recurrent or metastatic head and neck squamous cell cancer.

Innate Pharma Says Chemo-Free Monalizumab Triplet Therapy Shows Preliminary Anti-Cancer Activity

MARSEILLE, France--(BUSINESS WIRE)--Monalizumab combined with cetuximab and durvalumab demonstrates anti-tumor activity in first-line r/m head and neck cancer at ESMO IO 2021 congress

Innate Pharma: Monalizumab Combined With Cetuximab and Durvalumab Demonstrates Anti-Tumor Activity in First-Line Recurrent or Metastatic Head and Neck Cancer at ESMO Immuno-Oncology 2021 Congress

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to present monalizumab data at ESMO Immuno-Oncology 2021 Congress

News for Innate Pharma SA Stock (IPHA)